Latest Ebos (ASX:EBO) News

Neurizon and Clever Culture Systems led the week with 35.71% gains, while CONNEQT also rose despite giving back part of its reopening move.
Biotech trial funding, device manufacturing and healthcare launches shaped investor decisions across the sector.

EBOS Group has confirmed a total FY2026 final distribution of NZD 0.63670588 per share, with payment due on 18 September. The update also fixes the dividend reinvestment price at NZD 20.47, a 2% discount to the relevant NZX VWAP.

EBOS Group has fixed the dividend reinvestment price for its 2026 final distribution at NZD 20.47 per share, representing a 2% discount to the relevant NZX VWAP. The total payment remains NZD 0.63670588 per share, with cash distributions due on 18 September.

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.

EBOS Group has trimmed its FY26 underlying EBITDA forecast by up to AUD 15 million due to surging fuel and logistics expenses, while maintaining its commitment to healthcare supply continuity.

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.

EBOS Group Limited has updated its interim dividend details for the six months ending December 2025, confirming a fully franked ordinary dividend and a supplementary dividend, alongside a Dividend Reinvestment Plan offering a 2% discount.

EBOS Group Limited has updated its interim dividend announcement, specifying the Dividend Reinvestment Plan strike price and confirming payment details for the six-month period ending December 2025.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

EBOS Group Limited reported a solid 13% increase in revenue for the first half of FY2026, alongside a 13% rise in net profit attributable to owners, while maintaining its interim dividend.

EBOS Group Limited has updated its Dividend Reinvestment Plan rules, offering shareholders new ways to reinvest dividends into additional shares. The changes, effective immediately, provide greater flexibility and maintain board discretion over share issuance terms.

EBOS Group Limited has updated its final dividend details for the six months ending June 2025, confirming a fully franked ordinary dividend and specifying the Dividend Reinvestment Plan strike price.